Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich Sells 7,879 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich sold 7,879 shares of Mirum Pharmaceuticals stock in a transaction on Monday, March 17th. The shares were sold at an average price of $44.21, for a total transaction of $348,330.59. Following the completion of the transaction, the chief operating officer now directly owns 18,672 shares in the company, valued at $825,489.12. The trade was a 29.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Peter Radovich also recently made the following trade(s):

• On Monday, February 3rd, Peter Radovich sold 2,627 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $48.22, for a total transaction of $126,673.94.
• On Friday, January 24th, Peter Radovich sold 3,177 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $47.92, for a total transaction of $152,241.84.
• On Tuesday, January 7th, Peter Radovich sold 1,998 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $42.82, for a total value of $85,554.36.

Mirum Pharmaceuticals Trading Down 1.9 %

Shares of MIRM opened at $44.31 on Wednesday. Mirum Pharmaceuticals, Inc. has a twelve month low of $23.14 and a twelve month high of $54.23. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. The firm has a market capitalization of $2.17 billion, a P/E ratio of -21.94 and a beta of 1.04. The firm’s 50-day moving average is $47.55 and its two-hundred day moving average is $43.60.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The firm had revenue of $99.41 million for the quarter, compared to analysts’ expectations of $96.64 million. On average, research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in MIRM. GF Fund Management CO. LTD. purchased a new stake in shares of Mirum Pharmaceuticals in the 4th quarter worth about $42,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Mirum Pharmaceuticals by 16.4% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 73,888 shares of the company’s stock valued at $3,055,000 after purchasing an additional 10,427 shares in the last quarter. Woodline Partners LP grew its position in shares of Mirum Pharmaceuticals by 22.2% in the fourth quarter. Woodline Partners LP now owns 404,404 shares of the company’s stock valued at $16,722,000 after purchasing an additional 73,399 shares during the last quarter. Squarepoint Ops LLC purchased a new position in shares of Mirum Pharmaceuticals during the 4th quarter worth approximately $897,000. Finally, Tema Etfs LLC acquired a new position in shares of Mirum Pharmaceuticals during the 4th quarter worth approximately $1,735,000.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on MIRM shares. Robert W. Baird lifted their price objective on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an “outperform” rating in a research report on Thursday, February 27th. HC Wainwright raised their price objective on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the company a “buy” rating in a research report on Friday, February 28th. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $58.20.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.